Search

Your search keyword '"Rilpivirine -- Product development -- Research"' showing total 5 results
Start Over Descriptor "Rilpivirine -- Product development -- Research" Publication Year Range Last 50 years
5 results on '"Rilpivirine -- Product development -- Research"'

1. Data on Antiretrovirals Discussed by a Researcher at Public Assistance - Paris Hospitals (AP-HP) (Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results)

Subjects
Drug therapy, Research, Product development, Public assistance -- Research, Cabotegravir -- Research -- Product development, Physical fitness -- Research, Rilpivirine -- Product development -- Research, Welfare -- Research
Abstract

2024 OCT 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on antiretrovirals. According to news reporting originating from [...]

Published
2024

2. ViiV Healthcare to present data from largest head-to-head randomised trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

Subjects
Pfizer Inc. -- Product development, Rilpivirine -- Product development -- Research, Health care industry -- Product development, Clinical trials -- Research, AIDS treatment -- Research, AIDS (Disease) -- Research -- Drug therapy -- Prevention, International relief -- United States, Pharmaceutical industry -- Product development, Health care industry, Pharmaceuticals and cosmetics industries, Biktarvy (Medication) -- Research -- Product development, Dovato (Medication) -- Research -- Product development
Abstract

GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will be presenting the largest head-to-head, randomised clinical trial [...]

Published
2024

3. ViiV Healthcare Presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation

Subjects
Medical research, Medicine, Experimental, Rilpivirine -- Product development -- Research, Sexually transmitted diseases -- Prevention, Clinical trials -- Research, General interest, News, opinion and commentary
Abstract

LONDON: ViiV Healthcare announces positive findings from its phase I study showing that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting (CAB-ULA), can be dosed at intervals of [...]

Published
2024

4. ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses

Subjects
Pfizer Inc. -- Product development, Medical research, Medicine, Experimental, Rilpivirine -- Product development -- Research, Clinical trials -- Research, Pharmaceutical industry -- Product development, Business, international
Abstract

Brentford, London, United: GlaxoSmithKline has issued the following press release: Data show for the first time a new ultra long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval Pharmacokinetic, [...]

Published
2024

5. Data on Clinical Trials and Studies Described by a Researcher at AIDS Healthcare Foundation [Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS[TM] App and Web Portal: A Cluster ...]

Subjects
Medical research, Medicine, Experimental, Rilpivirine -- Product development -- Research, Clinical trials -- Research, AIDS (Disease) -- Research, Health
Abstract

2024 APR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on clinical trials and studies. According to news reporting out [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results